Spine BioPharma, Inc., a development stage company committed to non-opiate, non-surgical therapies for Degenerative Disc ...

Canaccord analyst Kingsley Crane raised the firm’s price target on CrowdStrike (CRWD) to $420 from $370 and keeps a Buy rating on the shares.

Canaccord raised the firm’s price target on Okta (OKTA) to $100 from $94 and keeps a Hold rating on the shares. The firm said they reported ...

Would you like to be notified of the latest news and updates on the stock market?

TTEC (NASDAQ:TTEC – Free Report) had its target price reduced by Canaccord Genuity Group from $4.50 to $3.50 in a research ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Core Scientific. If we consider the specifics ...

Clover Health Investments (NASDAQ:CLOV – Free Report) had its target price raised by Canaccord Genuity Group from $4.20 to $4.50 in a research report report published on Monday morning,Benzinga ...

Find insight on lithium, lumber, the impact of tariffs and more in the latest Market Talks covering Basic Materials.

Fintel reports that on February 28, 2025, Canaccord Genuity downgraded their outlook for ICF International (NasdaqGS:ICFI) ...

NuScale Power Corporation (NYSE: SMR) Q4 2024 Earnings Call Transcript March 3, 2025 NuScale Power Corporation beats earnings expectations. Reported EPS is $0.6, expectations were $-0.11.

Canaccord Genuity Sustainability Virtual Summit February 26, 2025 2:20 PM ETCompany ParticipantsRyan Corbett - Chief ...

CAMBRIDGE, Mass., March 04, 2025 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced that the ...